Brief: Helix Biopharma Q3 loss per share $0.03

Helix Biopharma

13/06/2017 22:59

June 13 (Reuters) - Helix Biopharma Corp  HBP.TO  : 
    * Q3 loss per share $0.03  
    * Co will require additional financing in near term, in 
future to see current research and development initiates through 
to completion 
    * Helix Biopharma Corp. announces fiscal third quarter 2017 
results 
    * Co's cash balance as at april 30, 2017 is insufficient to 
meet anticipated cash needs for working capital and capital 
expenditures 
    * Qtrly research and development costs totalled $1.9 million 
versus $1.5 million 
    * Cash balance as at april 30, 2017 is not sufficient to see 
current research and development initiates through to completion 
    * Considers securing additional funds, primarily through 
issuance of equity securities of co, to be critical for 
development needs 
    * As at april 30, 2017 co had working capital deficiency of 
$2 million, shareholders' deficiency of $1.5 million and a 
deficit of $154.1 million 
 
Source text : (http://reut.rs/2syhFp3) 
Further company coverage:  HBP.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))